Key points outlined in the article include:
- Suspension, termination, or withdrawal of >10,000 clinical trials registered with ClinicalTrials.gov potentially resulting in a significant delay in the development pipeline of novel therapies for urological malignancies
- Rapid development, registration, and commencement of new COVID-19 related clinical trials, now having doubled from the 1,409 reported at the time of publication, demonstrating a shift in resources away from oncological research
- Lessons learned about the structure of clinical trials design, focusing on streamlined implementation strategies, the value of flexibility in design, and a patient centered-approach
The ability for the urological research community to adapt to the constraints placed upon them throughout COVID-19 has been a truly commendable effort. Historically at the forefront of social media in medicine, urological groups internationally were able to adapt in quick succession to provide virtual platforms for conference programs, providing a necessary platform for research dissemination and collaborative discussion.2-4 The ASCO GU Symposium, AUA Live, and the EAU Congress all provided comprehensive virtual conferences, which although lacking the usual benefits of in-person networking and vibrant discussion, have provided a new avenue for how scientific meetings may be provided in the future.
Written by: Ellen O’Connor, MD, (on behalf of all co-authors) Department of Surgery, Austin Hospital, University of Melbourne, Vic, Australia
- Teh, Jiasian, Ellen O’Connor, Jasamine Coles-Black, and Nathan Lawrentschuk. "Clinical trials in urological oncology: COVID-19 and the potential need for a new perspective." World journal of urology (2020): 1-3.
- "AUA Live - AUA Virtual Experience". 2020. Auavirtual.Org.
- "Urosource | Resource Centre". 2020. Urosource.Uroweb.Org.
- "ASCO Meetings". 2020. Meetings.Asco.Org.